JACK LIEBERMAN, M.D.; IRVING I. LASKY, M.D.; S. I. DULKIN, Ph.D.; OTTO E. LOBSTEIN, Ph.D.
Serum glutamic-oxalacetic transaminase (SGO-T) activity was originally demonstrated by LaDue, Wroblewski and Karmen in 1954 to be an aid in establishing the diagnosis of myocardial infarction.1 This observation has since been confirmed by a number of other investigators.2-10 Many of these same investigators have also demonstrated the value of the serum transaminase test as an index of liver cell injury.8-14 In this regard the test has even been shown to be of value epidemiologically in revealing preclinical hepatitis or chronic lingering infection where other liver function studies are not significantly affected.14 Active rheumatic carditis was also found to produce high
LIEBERMAN J, LASKY II, DULKIN SI, et al. SERUM GLUTAMIC-OXALACETIC TRANSAMINASE ACTIVITY IN CONDITIONS ASSOCIATED WITH MYOCARDIAL INFARCTION. I. BODILY TRAUMA*. Ann Intern Med. 1957;46:485–496. doi: https://doi.org/10.7326/0003-4819-46-3-485
Download citation file:
Published: Ann Intern Med. 1957;46(3):485-496.
Results provided by:
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use